Hinge Health, Inc.'s SEC filings document its public-company reporting as an emerging growth company operating a technology platform for musculoskeletal care. Its Form 8-K filings cover quarterly and annual financial results, furnished earnings releases, supplemental investor materials, non-GAAP financial measures and reconciliations, and Regulation FD disclosures.
The company’s filings also record governance and capital-structure matters, including proxy materials for director elections and auditor ratification, board appointments and committee assignments, share repurchase authorization, Class A common stock disclosures, and post-IPO lock-up matters. These documents provide formal disclosure on operating results, stockholder voting matters, board oversight, capital allocation and securities-related events.
Hinge Health, Inc. (HNGE) reported that investment funds associated with director Robinson Elliott sold shares of its Class A Common Stock on September 9, 2026.
Bessemer Venture Partners X L.P. sold 5,489 shares and Bessemer Venture Partners X Institutional L.P. sold 5,848 shares at a weighted average price of $92.37, in multiple trades between $92.00 and $92.69. Elliott is a partner at Bessemer Venture Partners and has an indirect, passive economic interest in these shares and disclaims beneficial ownership except to the extent of any pecuniary interest.
Hinge Health, Inc. (HNGE) received a notice under Rule 144 that Executive Chairman and Co‑Founder Gabriel Mecklenburg may sell up to 400,000 shares of common stock through Morgan Stanley Smith Barney. The notice ties these shares to prior Performance Stock Units and Restricted Stock Units and discloses that 83,334 shares of common stock were sold in the past three months under a 10b5-1 trading plan.
Hinge Health, Inc. (HNGE) received a notice that officer James Budge intends to sell 55,561 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC on or after September 10, 2026. The shares were acquired upon vesting of restricted stock units between May 21, 2025 and September 1, 2026.
The planned sale has an indicated aggregate market value of $5,073,274.91. Hinge Health, Inc. reports that 62,468,721 shares of common stock are outstanding, providing context for the size of the proposed Rule 144 transaction.
Hinge Health, Inc. (HNGE) received a notice that Daniel Perez plans to sell up to 100,000 shares of common stock under Rule 144. The proposed sale is through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $9,131,000 and NYSE as the listed exchange.
The shares relate to restricted stock units acquired from the issuer on May 21, 2025. The filing lists 62,468,721 shares outstanding of the same class of common stock, which is a baseline figure and not the amount being sold.
Hinge Health, Inc. (HNGE) reports that stockholder Suthasini Mogun has filed a notice of proposed sale under Rule 144 for up to 150,000 shares of common stock. The shares, with an aggregate market value of $13,696,500, may be sold through Morgan Stanley Smith Barney LLC on the NYSE. The notice lists 62,468,721 shares of common stock as the relevant share count. The securities were acquired from restricted stock units vesting on May 21, 2025 and previously exercised stock options originally exercised on May 20, 2021.
Hinge Health, Inc. (HNGE) has a selling security holder, Bessemer Venture Partners X Institutional, filing a notice of proposed sale of Class A common stock under Rule 144. The filing lists up to 242,100 Class A shares to be sold through Merrill Lynch on the NYSE.
The securities to be sold were acquired from Hinge Health, Inc. in a private placement on February 4, 2020 for cash. The notice states that 62,468,721 Class A shares were outstanding as of the approximately expected sale date of September 9, 2026.
Hinge Health, Inc. (HNGE) received a Rule 144 notice that Bessemer Venture Partners X may sell 257,900 Class A shares of HNGE through Merrill Lynch on or about September 9, 2026. These shares were acquired on February 4, 2020 in a private placement for cash. Hinge Health, Inc. reports 62,468,721 Class A shares outstanding.
Hinge Health, Inc. (HNGE) director Robinson Elliott reported two indirect sales of Class A Common Stock associated with Bessemer venture funds. On September 4, 2026, Bessemer Venture Partners X L.P. and Bessemer Venture Partners X Institutional L.P. sold 7,450 and 6,994 shares, respectively, at a weighted average price of $92.17. On September 8, 2026, the same funds sold 21,006 and 19,719 shares, respectively, at a weighted average price of $92.58. The shares were sold in multiple transactions within disclosed price ranges, and Elliott disclaims beneficial ownership except for any indirect pecuniary interest.
Hinge Health, Inc. (HNGE) director-affiliated funds reported open-market sales of the company’s Class A Common Stock in early September 2026. On September 2, Bessemer Venture Partners X L.P. sold 35,918 shares and Bessemer Venture Partners X Institutional L.P. sold 33,717 shares at a weighted average price of $93.01 per share, in multiple trades between $92.72 and $93.52.
On September 3, 2026, the same funds sold 516 and 484 shares, respectively, at a weighted average price of $92.64 per share, in trades between $92.05 and $92.99. Reporting person Robinson Elliott, a partner at Bessemer Venture Partners, has an indirect, passive economic interest and disclaims beneficial ownership beyond any pecuniary interest.
Hinge Health, Inc. (HNGE) received a notice that the Michael Triplett 2012 Irrevocable Trust, identified as a 10% stockholder, has filed a Form 144 indicating an intention to dispose of up to 13,774 Class A shares through Raymond James & Associates, Inc.
The filing lists an approximate aggregate market value of $1,239,660 for these shares, based on trading on the NYSE as of September 3, 2026, when 62,468,721 Class A shares were outstanding. The planned transfer is described as an in-kind distribution from various Insight entities, and extensive prior Class A share sales by Insight-affiliated funds and related parties over the prior three months are also disclosed.